1
项与 Anti-MSLN|PD-1 CAR-T (Ningbo Cancer Hospital) 相关的临床试验PD-1 Antibody Expressing Chimeric Antigen Receptor T Cells for Mesothelin Positive Advanced Malignancies
This is a single-arm, open-label, one center, dose escalation clinical study, to determine the safety and efficacy of infusion of autologous T cells engineered to express immune checkpoint antibody and chimeric antigen receptor targeting mesothelin in adult patients with mesothelin positive, recurrent or refractory malignant tumors.
100 项与 Anti-MSLN|PD-1 CAR-T (Ningbo Cancer Hospital) 相关的临床结果
100 项与 Anti-MSLN|PD-1 CAR-T (Ningbo Cancer Hospital) 相关的转化医学
100 项与 Anti-MSLN|PD-1 CAR-T (Ningbo Cancer Hospital) 相关的专利(医药)
100 项与 Anti-MSLN|PD-1 CAR-T (Ningbo Cancer Hospital) 相关的药物交易